Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

Lorenzo Rossi, Amelia McCartney, Emanuela Risi, Irene De Santo, Ilenia Migliaccio, Luca Malorni, Laura Biganzoli, Angelo Di Leo

Research output: Contribution to journalReview ArticleResearchpeer-review

12 Citations (Scopus)


The landscape of therapeutic options for the treatment of hormone receptor (HR)-positive (HR+) HER2 breast cancer (BC) has been profoundly changed by the introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into the metastatic setting. Currently all CDK4/6 inhibitors are approved only in the metastatic setting by Food and Drug Administration (FDA) and European Medicine Agency (EMA), whereas their role in the neoadjuvant setting is still at an investigational stage. Exploitation of novel agents such as CDK4/6 inhibitors to improve the efficacy of neoadjuvant endocrine therapy (ET) or to overcome de novo resistance to ET is an area of research under active evaluation. We present a review of the currently available data and ongoing clinical trials that are evaluating the role of CDK4/6 inhibitors in neoadjuvant therapy of HR+ HER2 early BC, and also illustrate translational aspects, such as the potential biomarkers of response to these new therapeutic agents.

Original languageEnglish
Pages (from-to)392-398
Number of pages7
JournalClinical Breast Cancer
Issue number6
Publication statusPublished - Dec 2019
Externally publishedYes


  • Biomarkers
  • CDK4/6 inhibitors
  • Early breast cancer
  • Neoadjuvant therapy
  • Preoperative

Cite this